|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Capitalization1 |
5 023 | 6 518 | 41 340 | 102 976 | 54 855 | - | - |
Enterprise Value (EV)1 |
4 398 | 5 548 | 36 842 | 92 848 | 36 333 | 32 192 | 29 618 |
P/E ratio |
-12,5x | -12,6x | -53,3x | 8,98x | 5,08x | 17,5x | 39,7x |
Yield |
- | - | - | - | - | - | - |
Capitalization / Revenue |
37,2x | 108x | 51,5x | 5,58x | 2,49x | 5,55x | 7,78x |
EV / Revenue |
32,6x | 92,1x | 45,9x | 5,03x | 1,65x | 3,26x | 4,20x |
EV / EBITDA |
-11,3x | -10,8x | -50,3x | 6,86x | 2,65x | 7,55x | 9,62x |
Price to Book |
- | 6,14x | 16,3x | 7,24x | 2,19x | 1,83x | 1,66x |
Nbr of stocks (in thousands) |
328 948 | 333 250 | 395 710 | 405 450 | 397 760 | - | - |
Reference price (USD) |
15,3 | 19,6 | 104 | 254 | 138 | 138 | 138 |
Announcement Date |
03/06/2019 | 02/26/2020 | 02/25/2021 | 02/24/2022 | - | - | - |
1 USD in Million |
|
|
Income Statement Evolution (Annual data) |
|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Net sales1 |
135 | 60,2 | 803 | 18 471 | 22 022 | 9 885 | 7 046 |
EBITDA1 |
-388 | -515 | -732 | 13 528 | 13 713 | 4 263 | 3 080 |
Operating profit (EBIT)1 |
-413 | -546 | -763 | 13 296 | 13 647 | 4 233 | 1 770 |
Operating Margin |
-306% | -906% | -95,0% | 72,0% | 62,0% | 42,8% | 25,1% |
Pre-Tax Profit (EBT)1 |
-384 | -515 | -745 | 13 285 | 13 610 | 4 202 | 1 576 |
Net income1 |
-402 | -514 | -747 | 12 202 | 11 474 | 3 351 | 1 554 |
Net margin |
-298% | -854% | -93,0% | 66,1% | 52,1% | 33,9% | 22,0% |
EPS2 |
-1,22 | -1,55 | -1,96 | 28,3 | 27,2 | 7,89 | 3,47 |
Dividend per Share2 |
- | - | - | - | - | - | - |
Announcement Date |
03/06/2019 | 02/26/2020 | 02/25/2021 | 02/24/2022 | - | - | - |
1 USD in Million 2 USD |
|
|
Income Statement Evolution (Quarterly data) |
|
Fiscal Period: December
|
2019 Q4 |
2020 Q1 |
2020 Q2 |
2020 Q3 |
2020 Q4 |
2021 Q1 |
2021 Q2 |
2021 Q3 |
2021 Q4 |
2022 Q1 |
2022 Q2 |
2022 Q3 |
2022 Q4 |
2023 Q1 |
2023 Q2 |
Net sales1 |
14,1 | 8,39 | 66,4 | 158 | 571 | 1 937 | 4 354 | 4 969 | 7 211 | 6 066 | 4 105 | 5 932 | 6 128 | 3 205 | 2 430 |
EBITDA |
-122 | - | - | - | - | - | - | - | 5 488 | - | - | - | - | - | - |
Operating profit (EBIT)1 |
-131 | -131 | -122 | -235 | -275 | 1 266 | 3 062 | 3 558 | 5 410 | 4 227 | 2 226 | 3 590 | 3 616 | 1 405 | 735 |
Operating Margin |
-929% | -1 560% | -184% | -149% | -48,2% | 65,4% | 70,3% | 71,6% | 75,0% | 69,7% | 54,2% | 60,5% | 59,0% | 43,9% | 30,3% |
Pre-Tax Profit (EBT)1 |
-124 | -124 | -117 | -233 | -271 | 1 260 | 3 063 | 3 552 | 5 410 | 4 229 | 2 150 | 3 729 | 3 680 | 1 413 | 743 |
Net income1 |
-124 | -124 | -117 | -234 | -272 | 1 221 | 2 780 | 3 333 | 4 868 | 3 657 | 1 914 | 2 998 | 2 865 | 1 139 | 595 |
Net margin |
-884% | -1 481% | -176% | -148% | -47,7% | 63,0% | 63,8% | 67,1% | 67,5% | 60,3% | 46,6% | 50,5% | 46,8% | 35,6% | 24,5% |
EPS2 |
-0,37 | -0,35 | -0,31 | -0,59 | -0,69 | 2,84 | 6,46 | 7,70 | 11,3 | 8,58 | 4,76 | 7,13 | 6,67 | 2,69 | 1,40 |
Dividend per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date |
02/26/2020 | 05/07/2020 | 08/05/2020 | 10/29/2020 | 02/25/2021 | 05/06/2021 | 08/05/2021 | 11/04/2021 | 02/24/2022 | 05/04/2022 | - | - | - | - | - |
1 USD in Million 2 USD |
|
|
|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Net Debt1 |
- | - | - | - | - | - | - |
Net Cash position1 |
625 | 971 | 4 498 | 10 128 | 18 522 | 22 663 | 25 237 |
Leverage (Debt / EBITDA) |
1,61x | 1,89x | 6,15x | -0,75x | -1,35x | -5,32x | -8,19x |
Free Cash Flow1 |
-437 | -491 | 1 960 | 13 336 | 8 501 | 4 816 | 2 573 |
ROE (Net Profit / Equities) |
-39,3% | -38,0% | -40,0% | 146% | 58,4% | 10,9% | 3,79% |
Shareholders' equity1 |
1 023 | 1 353 | 1 868 | 8 353 | 19 631 | 30 697 | 40 987 |
ROA (Net Profit / Asset) |
-25,3% | -28,9% | -16,7% | 76,2% | 40,4% | 6,29% | 0,83% |
Assets1 |
1 591 | 1 776 | 4 463 | 16 003 | 28 393 | 53 305 | 187 800 |
Book Value Per Share2 |
- | 3,19 | 6,42 | 35,1 | 63,1 | 75,3 | 83,1 |
Cash Flow per Share2 |
-1,01 | - | 5,32 | 31,6 | 19,9 | 6,60 | 1,36 |
Capex1 |
106 | 31,6 | 67,4 | 284 | 703 | 478 | 396 |
Capex / Sales |
78,3% | 52,4% | 8,40% | 1,54% | 3,19% | 4,83% | 5,63% |
Announcement Date |
03/06/2019 | 02/26/2020 | 02/25/2021 | 02/24/2022 | - | - | - |
1 USD in Million 2 USD |
|
| |
|
|
Pfizer's $11.6 billion Biohaven buy could spark more biotech deals |
Capitalization (USD) |
54 855 014 989 |
Net sales (USD) |
18 471 000 000 |
Number of employees |
2 700 |
Sales / Employee (USD) |
6 841 111 |
Free-Float |
90,6% |
Free-Float capitalization (USD) |
49 679 895 488 |
Avg. Exchange 20 sessions (USD) |
923 330 319 |
Average Daily Capital Traded |
1,68% |
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
|